New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
10:55 EDTAMGN, AMGN, NVS, NVS, MRK, MRK, INCY, INCY, GSK, GSK, EXEL, EXEL, BMY, BMY, AZN, AZN, ARRY, ARRY, RHHBY, RHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Biotech and Pharmaceuticals Analysts Liang and Kapur discuss the market opportunity and role of immunotherapy in the adjuvant melanoma setting ahead of the upcoming ASCO Annual Meeting on an Analyst/Industry conference call. Relevant companies AMGN, ARRY, AZN, BMY, EXEL, GSK, INCY, MRK, NVS and RHHBY may be discussed on the Analyst/Industry conference call to be held on May 28 at 11:30 am.
News For AMGN;ARRY;AZN;BMY;EXEL;GSK;INCY;MRK;NVS;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 26, 2015
07:44 EDTNVSNovartis drug Farydak recommended by CHMP for EU approval
Subscribe for More Information
June 25, 2015
14:03 EDTRHHBYRoche initiated with a Buy at HSBC
Subscribe for More Information
14:02 EDTNVSNovartis initiated with a Buy at HSBC
Price target CHF 115.
14:01 EDTGSKGlaxoSmithKline initiated with a Buy at HSBC
Price target GBP 17.
14:00 EDTAZNAstraZeneca initiated with a Hold at HSBC
Price target GBP 46.40.
10:11 EDTARRYOptions with decreasing implied volatility
Subscribe for More Information
09:34 EDTBMYBristol-Myers expects Waltham site to close in early 2018
Subscribe for More Information
09:32 EDTBMYBristol-Myers opens research site in Cambridge, discontinues virology research
Subscribe for More Information
07:11 EDTINCYImmunoVaccine announces collaboration with Incyte
Subscribe for More Information
June 24, 2015
13:37 EDTGSKGSK says CDC committee votedfor meningococcal group B vaccines
GlaxoSmithKline (GSK) announced that the U.S. Centers for Disease Control Advisory Committee on Immunization Practices voted for a Category B recommendation for meningococcal group B vaccination, including Bexsero, in individuals aged 16 to 23. Bexsero was approved by the FDA in January for use in individuals aged 10 through 25 years and acquired by GSK in March following the closure of the three-part transaction with Novartis (NVS).
09:07 EDTRHHBY, MRK, AZNCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bathís School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesnít anticipate a sale, the report noted. Reference Link
07:56 EDTAMGNAmgen management to meet with Evercore ISI
Subscribe for More Information
07:29 EDTBMYFDAnews to hold a summit
Subscribe for More Information
06:50 EDTAZNAstraZeneca loses top executive Ward-Lilley to Vectura, Reuters reports
Subscribe for More Information
June 23, 2015
10:30 EDTARRYOptions with decreasing implied volatility
Subscribe for More Information
07:31 EDTAZNBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
07:25 EDTGSK, INCY, AMGNPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
08:52 EDTBMYPortola, Bristol-Myers, and Pfizer announce results from Phase 3 ANNEXA study
Subscribe for More Information
07:01 EDTGSKPfizer to acquire Nimenrix, Mencevax from GlaxoSmithKline for $130M
Pfizer (PFE) announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130M. This transaction will add two high-quality and complementary vaccines to Pfizerís portfolio, allowing the company to reach a broader global population. Nimenrix is a single dose meningococcal ACWY-TT conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. Mencevax is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic or highly epidemic. Pfizer does not expect this transaction to have any significant impact on its 2015 financial performance. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, and is expected to occur in the second half of 2015. Pfizerís legal advisors for the transaction were Ropes & Gray and Clifford Chance.
05:35 EDTBMYAllied-Bristol Life Sciences licenses IP from Harvard University
Allied-Bristol Life Sciences, a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb, announced that it has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Malcolm Whitmanís lab at the Harvard School of Dental Medicine. Building on previous studies conducted with Mark Sundrud, PhD, and Anjana Rao, PhD, at Boston Childrenís Hospital, Professor Whitmanís lab, in collaboration with Professor Ralph Mazitschek, PhD, at the Center for Systems Biology at Massachusetts General Hospital, has shown that HF works through inhibition of Prolyl-tRNA synthetase, which leads to activation of an amino acid restriction response pathway. Based on this novel and differentiated mechanism, several lead molecules have been identified by the groups at HMS and MGH that have the potential to lead to effective therapy for several conditions including fibrotic and autoimmune diseases. The licensing agreement with Harvardís Office of Technology Development is among the first in a series of discovery and development projects that Allied-Bristol Life Sciences intends to pursue. The license to the technology from Professor Whitmanís lab will be held by a new ABLS subsidiary specifically formed to pursue further research and pre-clinical development of the technology and associated molecules.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use